Cargando…
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment
Clinical trials have confirmed that chimeric antigen receptor (CAR) T cell therapies are revolutionizing approaches for treating several relapsed or refractory hematological tumors. Cytokine release syndrome (CRS) is an adverse event with high incidence during CAR-T treatment. A further understandin...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940756/ https://www.ncbi.nlm.nih.gov/pubmed/33708205 http://dx.doi.org/10.3389/fimmu.2021.611366 |
_version_ | 1783662009273810944 |
---|---|
author | Yan, Zhiling Zhang, Huanxin Cao, Jiang Zhang, Cheng Liu, Hui Huang, Hongming Cheng, Hai Qiao, Jianlin Wang, Ying Wang, Yan Gao, Lei Shi, Ming Sang, Wei Zhu, Feng Li, Depeng Sun, Haiying Wu, Qingyun Qi, Yuekun Li, Hujun Wang, Xiangmin Li, Zhenyu Liu, Hong Zheng, Junnian Qian, Wenbin Zhang, Xi Xu, Kailin |
author_facet | Yan, Zhiling Zhang, Huanxin Cao, Jiang Zhang, Cheng Liu, Hui Huang, Hongming Cheng, Hai Qiao, Jianlin Wang, Ying Wang, Yan Gao, Lei Shi, Ming Sang, Wei Zhu, Feng Li, Depeng Sun, Haiying Wu, Qingyun Qi, Yuekun Li, Hujun Wang, Xiangmin Li, Zhenyu Liu, Hong Zheng, Junnian Qian, Wenbin Zhang, Xi Xu, Kailin |
author_sort | Yan, Zhiling |
collection | PubMed |
description | Clinical trials have confirmed that chimeric antigen receptor (CAR) T cell therapies are revolutionizing approaches for treating several relapsed or refractory hematological tumors. Cytokine release syndrome (CRS) is an adverse event with high incidence during CAR-T treatment. A further understanding of the characteristics and related risk factors of CRS is important for effective management. A total of 142 patients with relapsed or refractory acute lymphocyte leukemia (ALL), lymphoma, or multiple myeloma (MM) received lymphodepletion chemotherapy followed by infusion of CAR-T cells. The characteristics of CRS at different time points after treatment were monitored and risk factors were analyzed. The incidence of CRS for ALL, lymphoma, and multiple myeloma were 82%, 90%, and 90% respectively. Fever was observed on a median of day 3 for ALL, day 1 for lymphoma, and day 8.5 for MM after CAR-T cell infusion, and the duration was different between grade 1–2 CRS and grade 3–5 CRS. Disease types, peak concentration of IL-6, and CRP were associated with CRS. For patients with ALL, numbers of lymphoblast in bone marrow before lymphodepletion, peak concentration of IL-6, and CRP were independent risk factors of CRS. Clinical stage of lymphoma patients and high tumor burden in marrow of MM patients were independent risk factors of CRS. In conclusion, the characteristics and risk factors of CRS in different B-cell hematological tumors are different and should be managed individually during CAR-T cell therapy. |
format | Online Article Text |
id | pubmed-7940756 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79407562021-03-10 Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment Yan, Zhiling Zhang, Huanxin Cao, Jiang Zhang, Cheng Liu, Hui Huang, Hongming Cheng, Hai Qiao, Jianlin Wang, Ying Wang, Yan Gao, Lei Shi, Ming Sang, Wei Zhu, Feng Li, Depeng Sun, Haiying Wu, Qingyun Qi, Yuekun Li, Hujun Wang, Xiangmin Li, Zhenyu Liu, Hong Zheng, Junnian Qian, Wenbin Zhang, Xi Xu, Kailin Front Immunol Immunology Clinical trials have confirmed that chimeric antigen receptor (CAR) T cell therapies are revolutionizing approaches for treating several relapsed or refractory hematological tumors. Cytokine release syndrome (CRS) is an adverse event with high incidence during CAR-T treatment. A further understanding of the characteristics and related risk factors of CRS is important for effective management. A total of 142 patients with relapsed or refractory acute lymphocyte leukemia (ALL), lymphoma, or multiple myeloma (MM) received lymphodepletion chemotherapy followed by infusion of CAR-T cells. The characteristics of CRS at different time points after treatment were monitored and risk factors were analyzed. The incidence of CRS for ALL, lymphoma, and multiple myeloma were 82%, 90%, and 90% respectively. Fever was observed on a median of day 3 for ALL, day 1 for lymphoma, and day 8.5 for MM after CAR-T cell infusion, and the duration was different between grade 1–2 CRS and grade 3–5 CRS. Disease types, peak concentration of IL-6, and CRP were associated with CRS. For patients with ALL, numbers of lymphoblast in bone marrow before lymphodepletion, peak concentration of IL-6, and CRP were independent risk factors of CRS. Clinical stage of lymphoma patients and high tumor burden in marrow of MM patients were independent risk factors of CRS. In conclusion, the characteristics and risk factors of CRS in different B-cell hematological tumors are different and should be managed individually during CAR-T cell therapy. Frontiers Media S.A. 2021-02-23 /pmc/articles/PMC7940756/ /pubmed/33708205 http://dx.doi.org/10.3389/fimmu.2021.611366 Text en Copyright © 2021 Yan, Zhang, Cao, Zhang, Liu, Huang, Cheng, Qiao, Wang, Wang, Gao, Shi, Sang, Zhu, Li, Sun, Wu, Qi, Li, Wang, Li, Liu, Zheng, Qian, Zhang and Xu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Yan, Zhiling Zhang, Huanxin Cao, Jiang Zhang, Cheng Liu, Hui Huang, Hongming Cheng, Hai Qiao, Jianlin Wang, Ying Wang, Yan Gao, Lei Shi, Ming Sang, Wei Zhu, Feng Li, Depeng Sun, Haiying Wu, Qingyun Qi, Yuekun Li, Hujun Wang, Xiangmin Li, Zhenyu Liu, Hong Zheng, Junnian Qian, Wenbin Zhang, Xi Xu, Kailin Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment |
title | Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment |
title_full | Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment |
title_fullStr | Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment |
title_full_unstemmed | Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment |
title_short | Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment |
title_sort | characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor t cell treatment |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940756/ https://www.ncbi.nlm.nih.gov/pubmed/33708205 http://dx.doi.org/10.3389/fimmu.2021.611366 |
work_keys_str_mv | AT yanzhiling characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT zhanghuanxin characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT caojiang characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT zhangcheng characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT liuhui characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT huanghongming characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT chenghai characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT qiaojianlin characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT wangying characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT wangyan characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT gaolei characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT shiming characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT sangwei characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT zhufeng characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT lidepeng characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT sunhaiying characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT wuqingyun characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT qiyuekun characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT lihujun characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT wangxiangmin characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT lizhenyu characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT liuhong characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT zhengjunnian characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT qianwenbin characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT zhangxi characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment AT xukailin characteristicsandriskfactorsofcytokinereleasesyndromeinchimericantigenreceptortcelltreatment |